Growing evidence indicates that protein synthesis is deregulated in cancer onset and progression and targeting this process might be a selective way to combat cancers. While harmine is known to inhibit DYRK1A and intercalate into the DNA, tri-substitution was shown previously to modify its activity profile in favor of protein synthesis inhibition. In this study, we thus evaluated the optimized derivative CM16 in vitro anti-cancer effects unfolding its protein synthesis inhibition activity. Indeed, the growth inhibitory profile of CM16 in the NCI 60-cancer-cell-line-panel correlated with those of other compounds described as protein synthesis inhibitors. Accordingly, CM16 decreased in a time-and concentration-dependent manner the translation of neosynthesized proteins in vitro while it did not affect mRNA transcription. CM16 rapidly penetrated into the cell in the perinuclear region of the endoplasmic reticulum where it appears to target translation initiation as highlighted by ribosomal disorganization. More precisely, we found that the mRNA expression levels of the initiation factors EIF1AX, EIF3E and EIF3H differ when comparing resistant or sensitive cell models to CM16. Additionally, CM16 induced eIF2α phosphorylation. Those effects could explain, at least partly, the CM16 cytostatic anticancer effects observed in vitro while neither cell cycle arrest nor DNA intercalation could be demonstrated. Therefore, targeting protein synthesis initiation with CM16 could represent a new promising alternative to current cancer therapies due to the specific alterations of the translation machinery in cancer cells as recently evidenced with respect to EIF1AX and eIF3 complex, the potential targets identified in this present study.
Introduction
Among various processes that enable the continuous growth, multiplication and dissemination of malignant cells (Hanahan and Weinberg, 2011) , protein synthesis plays an important role in the onset and progression of cancer. Growing evidence indicates that targeting mRNA translation as a cancer therapy has the potential of selectively eradicating cancerous cells (Bhat et al., 2015; Nasr and Pelletier, 2012; Spilka et al., 2013) . In eukaryotic cells, mRNA translation occurs in four stages: initiation, elongation, termination and ribosome recycling. Among these, initiation is believed to be pivotal in the regulation of translation (Sonenberg and Hinnebusch, 2009) , and is often altered in cancer through dysregulation of expression and/or phosphorylation status of translation initiation proteins, including eIF2α, eukaryotic translation initiation factor 3 (eIF3) and members of the eukaryotic translation initiation factor 4F complex (eIF4F) (Bhat et al., 2015; Blagden and Willis, 2011; Silvera et al., 2010) . Translational control contributes to maintain several oncogenic programs (Silvera et al., 2010) and is reciprocally affected by oncogenic signaling pathways, which include MAPK and PI3K-AKT-mTOR (Bader et al., 2005; Topisirovic and Sonenberg, 2011) . In response to energy and nutrient demand, mTOR is activated by the PI3K signaling cascade and promotes the assembly of the eIF4F complex resulting in the capdependent translation (Hay and Sonenberg, 2004; Ma and Blenis, 2009) . Thus, the elevated activity of the translation machinery components and regulators makes them potential selective therapeutic targets to combat cancer cells (Bhat et al., 2015; Blagden and Willis, 2011; Malina et al., 2012) .
Harmine, a natural β-carboline, is known to exert anticancer properties through i) the inhibition of DYRK1A (Göckler et al., 2009; Seifert et al., 2008) , a protein kinase linked to tumorigenesis (Abbassi et al., 2015; Laguna et al., 2008; Pozo et al., 2013) and ii) DNA intercalating properties (Nafisi et al., 2010; Sarkar et al., 2014) . Although displaying more potent growth inhibition than harmine itself, 2,7,9-tri-substituted β-carbolines exhibit no effect on DYRK1A, but instead were found to be possible protein synthesis inhibitors (Frédérick et al., 2012) . Optimization of their pharmacological and physico-chemical properties led to the identification of CM16 as the lead compound, which to the best of our knowledge is the first harmine-derived beta-carboline (Meinguet et al., 2015) to be studied for its potential as protein synthesis inhibitor of cancer cells. The present study examines the anti-cancer properties of CM16 at the cellular level and on protein synthesis in three cancer cell models of different histological origins, i.e. the melanoma SKMEL-28, the glioma Hs683 and the breast cancer MDA-MB-231 models. We discovered EIF1AX and eIF3 complex members, recently identified as potential cancer targets, as possible regulators of cancer cell sensitivity to CM16.
Materials and methods

Cell lines and compounds
The human cancer cell lines, oligodendroglioma Hs683 (ATCC code HTB-138), melanoma SKMEL-28 (ATCC code HTB-72) and breast adenocarcinoma MDA-MB-231 (ATCC HTB26), as well as the normal human cell lines, skin fibroblasts NHDF (Lonza CC-2509), and lung fibroblasts NHLF (Lonza CC-2512) were selected for the current investigation. Cells were cultivated at 37°C with 5% CO 2 in RPMI culture medium supplemented with 10% FBS, 200U penicillin-streptomycin, 0.1 mg/ml gentamicin and 4 mM L-glutamine, or fibroblast medium FBM supplemented with 2% fetal bovine serum, 0.1% insulin, rhFGF-B and gentamicin. MDA-MB-231 cells were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin/streptomycin, and 2 mM L-glutamine at 37°C and 5% CO 2 . CM16 was synthetized as previously described (Meinguet et al., 2015) .
MTT colorimetric assay
Cells were first grown in 96 well plates for 24 h and then treated with CM16 at different concentrations up to 100 µM or left untreated for 72 h. Viability was estimated by means of the MTT -3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (Sigma, Bornem, Belgium) mitochondrial reduction into formazan as previously described (Mosmann, 1983) . Two experiments were performed in non-cancerous cell lines (NHDF and NHLF) and three in cancerous cell lines (Hs683, SKMEL-28 and MDA-MB-231), each in sextuplicate.
Quantitative videomicroscopy
Computer-assisted phase contrast microscopy was performed as previously described (Debeir et al., 2008) . Briefly, Hs683, SKMEL-28 or MDA-MB-231 cells were seeded in 25 cm 2 culture flasks and left untreated or treated with CM16 at their GI 50 concentrations determined with the MTT colorimetric assay or at the concentration 10 times higher. Pictures of one field were taken every four min during a 72 h period and further compiled into a short movie (Debeir et al., 2008) . Quantitatively, global growth ratio was determined based on cell counting of pictures corresponding to 24 h, 48 h and 72 h in comparison to 0 h. Experiments were performed once in triplicates.
Fluorescence assays
CM16 cell penetration and distribution analysis
The fluorescence properties of CM16 were first determined in a phosphate buffer at pH 7.4 as ex/em: 330/439 nm. To qualitatively analyze the CM16 cell penetration and distribution, tumor cells (Hs683, SKMEL-28 and MDA-MB-231) were seeded on glass coverslips in cell culture plates and, after attachment, treated with 5 µM CM16 or left untreated. For imaging of the living cells, medium was removed and PBS was added. Coverslips were rapidly transferred to a slide and images were captured with the Imager M2 fluorescence microscope (Carl Zeiss, Zaventem, Belgium) coupled with the AxioCam ICm1 and AxioImager software (Carl Zeiss, Zaventem, Belgium). The experiment was conducted twice in duplicate and three images per condition were taken.
Ribosome fluorescent staining
Endoplasmic reticulum (ER) staining of cells was performed with glibenclamide ER-tracker red dye (Molecular Probes -Life Technologies, Merelbeke, Belgium) by fluorescence microscopy. Cells were seeded on coverslips in cell culture plates and left untreated or treated with CM16 after attachment (at least 24 h). Following treatment, the dye solution (1 µM in PBS) was incubated with the samples for 30 min at 37°C. The staining solution was replaced with cell culture medium and sample-containing coverslips were transferred to microscope slides. The imaging of living cells was performed similarly to description above (item a) with fluorescence microscope (Carl Zeiss, Zaventem, Belgium). Experiments were conducted once or twice, depending on the cell line, in duplicate and five images per condition were taken.
Protein neosynthesis evaluation
Fluorescence method
To evaluate the effects of CM16 on neosynthesized proteins the Click-iT AHA alexa fluor 488 kit (Invitrogen, Life Technologies, Merelbeke, Belgium) was used. A methionine analog L-azidohomoalanine is incorporated in newly synthesized proteins and reacts with an alkyne coupled to alexa 488 fluorescent dye allowing measurement (ex/ em: 495/520 nm). Hs683, SKMEL-28 and NHDF cells were seeded in 96 wells plates and left untreated or treated with CM16 or positive control, i.e. cycloheximide (Santa Cruz Biotech., Heidelberg, Germany). The treatment was followed by the addition of L-azidohomoalanine (1/ 1000) for four h. After fixation with formaldehyde, the neosynthesized proteins were stained according to the manufacturer's recommendations. Normalization according to cell number was carried out as described in the user manual with Hoescht counterstaining. The fluorescent signal was measured in a microplate reader (SynergyMX Biotek, Winooski, USA: ex/em: 350/460 nm). Experiments were performed each in sextuplicate. MA) was added to the cells. At the end of the incubation, cells were washed twice with ice-cold PBS and labeling reactions were terminated through the addition of RIPA buffer. Newly synthesized radiolabeled proteins were precipitated on 3 MM Whatman paper (pre-blocked with 0.1% L-methionine) using trichloroacetic acid (TCA) and washed twice with 5% TCA, followed by two washes of ethanol. Samples were then dried and quantitated using scintillation counting. CPMs were normal-ized to total protein, which was determined using the DC Assay (Biorad). Experimental results represent three biological replicates, each performed in technical duplicate.
2.6. Investigation of the translation initiation: ribosome and polysome organization study Ribosomes and polysomes were separated through ultracentrifugation in sucrose gradient, as described in Cencic et al. (2007) . Briefly, Hs683, SKMEL-28, NHDF, NHLF cells were seeded in cell culture flasks and left untreated (negative control) or treated with puromycin or CM16. Cells were then scraped and collected in a PBS buffer containing 100 µg/ml cycloheximide and centrifuged (400×g, 4°C, 10 min). Pellets were resuspended in a hypotonic lysis buffer (5 mM Tris pH 7,5; 2,5 mM MgCl 2 ; 1,5 mM KCl), supplemented with cycloheximide 100 μg/ml, DTT 2 mM, 5 μL RNasin Ribonuclease Inhibitor (Promega, Leiden, Netherlands), 10 μL of 10% Triton X-100 and 10 μL of 10% sodium deoxycholate. Samples were centrifuged (16100 rcf, 2 min, 4°C) and loaded onto a 10 -50% sucrose gradient and centrifuged for 2 h at 156,213×g at 4°C (SW 60 Ti rotor, Beckman, Ramsey, USA). The obtained gradients were then collected in fractions through a constant pump flow and absorbance measurement carried out at 264 nm in a microplate reader (SynergyMX Biotek, Winooski, USA). Three independent experiments were carried out in the Hs683 and SKMEL-28 cancer cell lines and one experiment in the noncancerous non-transformed fibroblasts NHLF and NHDF.
For the polysomes generated using MDA-MB-231 cells, samples were loaded onto a 10-50% sucrose gradient and centrifuged for 2 h and 15 min at 217,290×g. The gradients were then fractionated while reading UV 254 absorbance using the Foxy® R1 fraction collector (Teledyne, ISCO). One experiment (or measurements) was performed.
Immunodetection
MDA-MB-231 or NHDF cells were treated with the indicated concentrations of CM16 for 60 min and lysates were collected by washing the cells with ice cold PBS followed lysis using a buffer composed of 20 mM HEPES [pH 7.5], 150 mM NaCl, 1% Triton-X100, 10% glycerol, 1 mM EDTA, 10 mM tetrasodium pyrophosphate, 100 mM NaF, 17.5 mM β-glycerophosphate, 1 mM PMSF, 4 mg/ml aprotinin, and 2 mg/ml pepstatin A. Samples were resolved on a 10% NuPAGE gel and transferred to a PVDF membrane (BioRad) for immunoblotting. The following antibodies were used in this study: eukaryotic elongation factor 2 (eEF2) (#9742, Cell Signaling), pan eIF2α (#9722, Cell Signaling), phospho-eIF2α (Ser51) (#9721, Cell Signaling). Two independent experiments were performed.
NCI data analysis
NCI GI 50 profile of CM16 was compared to those of the compounds in the NCI database with the COMPARE software tool of the NCI (Paull et al., 1989) . Only the compounds displaying a COMPARE correlation coefficient (CCC) with CM16 above 0.7 were considered in Table 1 .
Statistical analysis
For the transcriptomic comparison, we selected the models with GI 50 > 1 µM or < 0.1 µM as the least versus the most sensitive models of the NCI 60 cancer cell line panel. A list of potential candidates regulating or involved in protein synthesis was established based on the literature and includes the main components of the cap-dependent translation machinery, as well as kinases and important proteins involved in the protein synthesis pathways (Table 1 in Carvalho et al. (2017) ). Comparison of the two groups was performed by T-test comparison of the Z score with the Statistica Software. Z scores are provided by the NCI and are determined for each probe/cell line pair by the subtraction from its intensity in the transcriptomic array of the probe mean across the 60 cell lines, and division by the standard deviation of the probe (across the 60 cell lines). The z score average was then calculated as the mean across all probes and probe sets that passed quality control criteria.
Results
Evaluation of in vitro global growth inhibition by CM16
CM16 (Fig. 1 ) was evaluated at the National Cancer Institute (NCI -Bethesda, USA) in the 60 cancer cell line panel. Fig. 2A shows that the mean 50% growth inhibitory concentration (GI 50 ) obtained by the NCI is~0.2 µM and varies from < 0.01 to 4 µM. Of note, 80% of the cell lines display GI 50 close to the mean value, between 0.1 and 0.5 µM ( Fig. 2A) . The mean 50% lethal concentration (LC 50 ) in the NCI panel is 9 µM and ranges from 0.5 to > 100 µM (Fig. 2B) . Interestingly, the response profiles of the 60 cell lines based on the GI 50 values differ from those obtained with the LC 50 counterparts. For example, for the leukemia sub-panel these differential sensitivities are opposite to each other. These observations indicate that CM16 exerts cytostatic activity at lower concentrations (close to GI 50 ) through different mechanism(s) from that associated with its cytotoxic effects at higher concentrations (close to LC 50 ). Because CM16 does not display specificity towards one defined cancer type in the NCI panel, we decided to use cancer cell models of distinct origins, i.e., glioma (Hs683), melanoma (SKMEL-28) and breast carcinoma (MDA-MB-231), for the current investigation to limit cell-type specific and context-dependent factors. Moreover, while keeping the same sensitivity to CM16 effects, these three cell lines display different sensitivity to apoptosis -SKMEL-28 being apoptosis-resistant (Mathieu et al., 2009 ), while Hs683 (Branle et al., 2002) and MDA-MB-231 (Syed Alwi et al., 2012) are apoptosissensitive. We also included in our assay non-transformed cells, i.e. dermal and lung fibroblasts. The mean GI 50 was about an order of magnitude lower in cancer cell cultures than in non-cancerous models (i.e. 0.3 µM versus 3.8 µM respectively; Fig. 3A ) indicating moderate selectivity towards cancer cells. Importantly, our mean GI 50 of 0.3 µM on cancer cells (Fig. 3A) is similar to the one of the NCI (GI 50 : 0.2 µM).
CM16 exerts in vitro anticancer activity through cytostatic effects
The cytostatic activity of CM16 was confirmed by means of quantitative videomicroscopy in glioma Hs683, melanoma SKMEL-28 and MDAMB-231 breast cancer cells using the MTT-derived GI 50 concentrations as illustrated morphologically and quantitatively ( Fig. 3B-C) . We further investigated the cytostatic effects of CM16 at its GI 50 using flow cytometric cell cycle analysis but did not observe any significant effect as previously shown (Fig. 1A-B in Carvalho et al. (2017) ). Thus, CM16-induced growth inhibition is not related to a specific cell cycle phase or arrest. Accordingly, we observed that CM16 and its previously studied analogues (Frédérick et al., 2012) do not interact with DNA when assayed in vitro (data not shown), as opposed to harmine and related compounds that display DNA intercalating and groove binding properties (Nafisi et al., 2010; Sarkar et al., 2014) .
CM16 cellular penetration and distribution
Fluorescent properties of CM16 were used to study its cellular penetration and distribution by fluorescence microscopy. CM16 appeared to penetrate as early as 5 min after initiating treatment (Fig. 4A) in the perinuclear region, while the nucleus itself remained unstained even after 6 h of treatment (data not shown). Moreover CM16 appeared to co-localize with the endoplasmic reticulum ( Fig. 4B-D for Hs683, SKMEL-28 and MDA-MB-231, respectively), where the translation machinery is assembled. However, no obvious differences were revealed in cell penetration or distribution of CM16 between non-transformed fibroblasts and cancer cells that could explain, even partly, the selectivity we observed above (data not shown).
CM16 inhibits protein synthesis
To evaluate whether CM16 could be a protein synthesis inhibitor, its NCI GI 50 -based cellular sensitivity profile was compared to those of > 765,000 compounds in the NCI database using the COMPARE algorithm (Paull et al., 1989) . Among 11 compounds, displaying a COMPARE correlation coefficient (CCC) with CM16 above 0.7, mechanistic information was available for 8 (SCOPUS database as of September 2016), of which 6 have been described as potential protein synthesis inhibitors (Table 1) . Moreover, significant correlation (CCC of 0.71) was found with 5a, one of the previously studied analogues of CM16 (Table 1) (Frédérick et al., 2012) . Consequently, we investigated the effects of CM16 on newly synthesized proteins in transformed Hs683, SKMEL-28 and MDAMB-231 and in NHDF non-transformed cell lines (Fig. 5A-D) . Hs683 and SKMEL-28 cells were treated with 0.5 and 5.0 µM of CM16 from 1 to 6 h, treatment schedules that induced cytostatic effects only, as verified by videomicroscopy (Fig. 3C) . At 5 µM, the neosynthesized protein level was decreased by 50% after only a 1 h treatment in SKMEL-28 cells and 3 h in HS683 cells and the inhibition was concentration-dependent. At 0.5 µM, the treatment period had to be increased from 6 to 24 h to obtain a similar decrease (data not shown). Similarly, we observed a concentration-dependent decrease in incorporated 35 S methionine in MDA-MB-231 breast cancer cells after only 80 min of treatment with CM16, with the concentration of 10 µM leading to nearly a complete inhibition of protein synthesis (Fig. 5D) . Evaluation of newly synthesized proteins in NHDF normal fibroblast cells showed no significant different response than cancer cell model ( Fig. 5C and D) . We also envisaged effects at the transcription level but no alteration of the incorporation of a nucleotide analog into the newly-transcribed mRNA for up to 24 h and in the presence of up to 5.0 µM CM16 in Hs683 and SKMEL-28 cells lines could be observed ( Fig. 2A-B ). We concluded that CM16 does not inhibit transcription while it does inhibit mRNA translation, at least as a common feature across the different cellular models used in the present study.
CM16 affects ribosomal organization in cancer cells
To investigate the effects of CM16 on translation further, we evaluated the ribosomal assembly into 80S functional subunit and polysome organization by means of sucrose gradients. CM16 induced the accumulation of 80S ribosomes in treated cells, while polysomes decreased after 80 min of treatment at 10 µM (the concentration that completely inhibited 35 S methionine incorporation in 80 min) in MDA-MB-231 (Fig. 6A) . We confirmed that ribosomal organization in Hs683 and SKMEL-28 cells was affected as early as after a 3 h treatment with lower concentrations, i.e. 0.5 and 5.0 µM CM16 (Fig. 6B-C) . Again, we observed an accumulation of the fractions corresponding to the free 80S ribosome when compared to puromycin-induced effects (Fig. 6B) . Non-transformed fibroblasts also displayed similar altered profiles but at high concentrations only ( Fig. 6D-E) . Because actin plays critical roles in translation initiation and proper polysome organization (Gross and Kinzy, 2007) , fluorescent staining of fibrillary actin was performed in the absence or presence of 0.5 and 5.0 µM of CM16 over a 24 h period but no significant modification was noticed, at least in Hs683 and SKMEL-28 (data not shown).
Initiation factors are involved in CM16-induced inhibition of mRNA translation
Because the previous chemical series were shown to modify the eIF2α expression and activity levels (Frédérick et al., 2012) , we further investigated if CM16 could affect mRNA translation by eIF2α targeting. Its phosphorylation was observed in MDA-MB-231 cells when treated with 2.5 and 10 µM of CM16 for 80 min, an effect also found in NHDF cells (Fig. 7A) . To further evaluate whether the expression level of eIF2α and its partners eIF2β and eIF2γ could drive, at least partly, the sensitivity of cells to CM16, we utilized the NCI cell line transcriptomic Fig. 2A) , and without large variation, four cell lines appeared poorly sensitive to CM16 with GI 50 > 1 µM (least sensitive, LS) while five other appeared highly sensitive, i.e. those with a GI 50 < 0.1 µM (most sensitive, MS). We thus compared the transcriptomic expression levels of eIF2α and its partners eIF2β and eIF2γ between these two groups of cell lines displaying two orders of magnitude difference of sensitivity to CM16 but no statistical significance could be observed (Fig. 7B) . Eukaryotic translation initiation factor 2 alpha kinase 3 (PERK) is a key kinase regulating eIF2α phosphorylation (Ron, 2002) and thus activity. However, CM16 did not alter PERK kinase activity in vitro as shown in Fig. 3 in Carvalho et al. (2017) . We then extended the comparison of the highly versus poorly sensitive cell lines of the NCI to a more extensive list of 57 components, actors and regulators of translation (Table 1 in Carvalho et al. (2017) ). Interestingly among these 57 targets of the translation machinery selected, only three initiation factors were found to be significantly differentially expressed between the two groups: EIF1AX, EIF3E and EIF3H (Fig. 7C) , while neither elongation nor signaling pathways investigated were different (data not shown). The expression level of initiation factors could thus drive, at least partly, the sensitivity of a cell line to CM16 and further support the effects of this compound on the initiation phase of translation.
Discussion
Malignant cells require higher levels of protein synthesis to maintain several oncogenic programs (Silvera et al., 2010) and in recent years it has been extensively shown that several distinct dysregulations of the translation process occur in cancer cells (Nasr and Pelletier, 1 We did not perform proteomic comparison of these cell lines because some data were missing for several targets and cell lines rendering the analysis impossible to interpret.
A. Carvalho et al. European Journal of Pharmacology 805 (2017) 25-35 2012; Ruggero, 2013; Spilka et al., 2013) . Direct inhibitors of the translation machinery, targeting the eIF4F, eIF3 or the ternary complexes, are under investigation at different stages of development (for a detailed review of therapeutic inhibitors of translation in cancer, see (Bhat et al., 2015) ). Efforts toward this goal also include the development of inhibitors of upstream signaling pathways (e.g., PI3K-mTOR and MNK) (Bhat et al., 2015; Blagden and Willis, 2011; Malina et al., 2012) . Our research aimed at the elucidation of the anti-cancer potential of a preclinical candidate CM16, a β-carboline derived from a harmala alkaloid harmine (Meinguet et al., 2015) , which was investigated herein as a protein synthesis inhibitor in vitro. First, we observed that CM16 exerts cytostatic effects at its GI 50 concentration in cancer cells and that it displays at least 10 times more selectivity in inhibiting the growth of cancer cells as compared to non-cancerous cell lines (Fig. 3A) . Although cytostatic, CM16 did not induce any cell cycle phase arrest, which is consistent with the lack of its interaction with DNA as well as the absence of CM16 localization to the nucleus (Fig. 4A) .
We compared the growth inhibitory profile of CM16 in the 60 NCI cancer cell line panel to those of the existing compounds in the NCI database using the COMPARE software, which expresses and ranks the similarities in the differential cellular sensitivities as the Pearson correlation coefficient (Paull et al., 1989) . This approach has been successfully employed to identify new inhibitors of translation in the past (Chan et al., 2004) and it indeed supported CM16 as a protein synthesis inhibitor.
Further, the inhibition of translation induced by CM16 in different cancer models, such as melanoma, glioma and breast cancer cell lines, was found to be time-and concentration-dependent while no effect on transcription was observed. These results are consistent with the parallel intracellular distribution of CM16 with the endoplasmic reticulum ( Fig. 4B-D) , the major site for mRNA translation (Reid and Nicchitta, 2015) . Importantly, because no selectivity against a cancer type appeared in the NCI panel, we conducted the assays in cancer cell models from different origins, i.e. glioma, melanoma and breast cancer cell lines to avoid cell-type and context-dependent limitations. In fact, CM16 appeared to affect translation initiation as illustrated by ribosomal disorganization in the three cancer cell models used while those effects were observed at higher doses only in the non-cancerous models. Translation initiation is dependent on the formation of eIF4F complex (eIF4G, eIF4A and eIF4E), which recruits the 40S ribosomal unit, and the ternary complex (eIF2, tRNA met and GTP), necessary for initiation. Previous beta-carboline compound series was shown to decrease eIF2α expression and/ or phosphorylation levels (Frédérick et al., 2011) . In this study, preliminary data obtained with breast cancer cells indicate that CM16 could induce eIF2α phosphorylation (Fig. 7A ), which will in turn compromise the formation of the ternary complex and binding of tRNA met to the ribosome (Hinnebusch and Lorsch, 2012) , and thus inhibit protein synthesis (Koromilas, 2015) . Compared to harmine derivatives previously characterized, compound CM16 is less hydrophobic and does not bear large substituents like phenyl or cyclohexyl rings. At the present stage of our investigations, it is however difficult to link differences in eIF2α activity within this series and specific stereoelectronic properties and, thus, no A. Carvalho et al. European Journal of Pharmacology 805 (2017) 25-35 convincing (Q)SAR can be proposed. A family of four kinaseseukaryotic translation initiation factor 2 alpha kinase 1 (HRI), eukaryotic translation initiation factor 2 alpha kinase 2 (PKR), eukaryotic translation initiation factor 2 alpha kinase 4 (GCN2) and PERKregulates eIF2α phosphorylation (Koromilas, 2015; Ron, 2002; Wek et al., 2006) . While no direct effect of CM16 on PERK kinase activity in vitro could be evidenced (see Fig. 3 in Carvalho et al. (2017) ) it remains possible that CM16 acts, at least partly, through ER stress-mediated activation of PERK in cellular assay (Koromilas, 2015) and/or via the other kinases mentioned above. CM16 selectivity towards cancer cells was observed through the in vitro evaluation of growth inhibition (Fig. 3A) . We also observed that CM16-induced ribosomal disorganization was present but less pronounced in non-cancerous cell models (Fig. 6D-E) . Interestingly, targeting initiation proteins instead of elongation ones would offer greater selectivity in inhibiting the growth of cancer cells as elongation inhibitors seem to have a narrow therapeutic window due to the inhibition of global protein synthesis of non-transformed cells (Lindqvist et al., 2009; Malina et al., 2012) . Moreover, several initiation proteins are dysregulated in cancer cells as compared to normal cells. As CM16 induces phosphorylation of eIF2-α similarly in cancerous and non-cancerous cells (Fig. 7A) , it is unlikely that the effects on this initiation factor are responsible for the selectivity observed. Also, no difference in cell penetration and distribution of CM16 between non-cancerous and cancerous models could be found to explain this selectivity. Therefore, we extended the study to 57 genes involved in translation initiation and elongation or in their control using the transcriptomic characterization of the NCI 60 cell line panel. Among these 57 targets (see Table 1 in Carvalho et al. (2017) ), the mRNA levels of only three initiation factors, i.e. EIF1AX, EIF3E and EIF3H, were found to be significantly different in highly sensitive cancer cell lines compared to those with low sensitivity towards CM16 (Fig. 7C) . eIF1A, the protein encoded by EIF1AX, is important in the formation of the pre-initiation complex, composed of the 40S subunit, eukaryotic translation initiation factor 1 (eIF1), eukaryotic translation initiation factor 5 (eIF5), eIF3 and the ternary complex (Bhat et al., 2015; Spilka et al., 2013) , and together with eIF1, is required for mRNA scanning and binding at the initiation codon (Spilka et al., 2013) . Mutations in the EIF1AX gene have been associated with tumor development and progression in thyroid cancer (Jung et al., 2016; Landa et al., 2016) uveal melanomas Field et al., 2016) and possibly ovarian tumor carcinogenesis (Hunter et al., 2015) . Knowledge of its functional roles in cancer biology is still currently limited (Spilka et al., 2013) and warrant further investigations. Similarly, eIF3e and eIF3h have been both reported to be dysregulated in cancer (Bhat et al., 2015) . They are part of the largest initiation Increased expression levels as compared to the 60 cell line mean appear in black while decreased expression levels appear in grey. Results are expressed as Z scores as provided by the NCI database. Z scores are determined for each probe/cell line pair by the subtraction from its intensity of the probe mean (across the 60 cell lines), and division by the standard deviation of the probe (across the 60 cell lines). The z score average was then calculated as the mean across all probes and probe sets that passed quality control criteria.
complex, i.e. the eIF3 complex, which is composed of 10-13 subunits acting together in the initiation process. Their main roles include recruitment of the mRNA to the 40S ribosomal unit and stabilizing the ternary complex (Bhat et al., 2015; Spilka et al., 2013) . At the protein level, eIF3e affects proliferation and survival of glioblastoma cells (Sesen et al., 2014) , is involved in colon tumor progression (Li et al., 2014) and breast tumor formation, (Suo et al., 2015) progression (Grzmil et al., 2010) and metastasis (Gillis and Lewis, 2013) . High levels of eIF3h maintain the malignancy of several cancer cell lines in vitro (Zhang et al., 2008) and have been indeed observed in breast, prostate and hepatocellular carcinomas (Hershey, 2015; Zhu et al., 2016) . How the targeting of these initiation factors help to explain superior activity of CM16 against cancerous over non-cancerous cells remains to be investigated.
Conclusion
Translation inhibition in cancer is emerging as a new and promising alternative to the existing therapies due to the specific alterations of the translation machinery in cancer cells. The results of the present investigation show that CM16, a preclinical candidate derived from a harmala alkaloid harmine with favorable drug-like physico-chemical characteristics, inhibits cancer cell protein synthesis at the mRNA translation level via perturbation of their ribosomal organization. EIF1AX and EIF3 complex members, recently reported to be involved in cancer onset and progression, were found in the present study to be differentially expressed in cancer cell lines depending on their sensitivity towards CM16.
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